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The evaluation of quality, safety, and eﬃcacy of medicinal products by the European Medicines Evaluation Agency (EMEA) via
the centralized procedure is the only available regulatory procedure for obtaining marketing authorization for gene therapy (GT)
medicinal products in the European Union. The responsibility for the authorization of clinical trials remains with the national
competent authorities (NCA) acting in a harmonized framework from the scientiﬁc viewpoint. With the entry into force of a new
directive on good clinical practice implementation in clinical trials as of 1 May 2004, procedural aspects will also be harmonized
at EU level. Scientiﬁcally sound development of medicinal products is the key for the successful registration of dossiers and for
contributing to the promotion and protection of public health. The objective of this paper is to introduce the EMEA regulatory
processes and scientiﬁc activities relevant to GT medicinal products.
INTRODUCTION TO THE EMEA AND THE EU
MEDICINES NETWORK
The legal basis for the operation of the EMEA (Eu-
ropean Medicines Evaluation Agency) was established by
theCouncilRegulation2309/ECadoptedbytheEuropean
Council of Ministers [1] in July 1993.
The main objective of the EMEA mission is to con-
tribute to the protection and promotion of public and an-
imal health by
(i) mobilizing scientiﬁc resources from throughout
the European Union to provide high quality evaluation
of medicinal products, to advise on research and develop-
ment programmes and to provide useful and clear infor-
mation to users and health professionals;
(ii) developing eﬃcient and transparent procedures
to allow timely access, by users, to innovative medicines
through a single European marketing authorization;
(iii) controlling the safety of medicines for humans
and animals, in particular through a pharmacovigilance
network and the establishment of safe limits for residues
in food-producing animals.
The EMEA is a technical agency acting as a central
point of coordination of the existing scientiﬁc resources
in the European Union (EU) for the regulatory and sci-
entiﬁc evaluation of medicinal products both for human
and veterinary use [2, 3, 4]. The operations started in Jan-
uary 1995. The main tasks carried out by the EMEA can
be grouped in three categories:
(1) regulatory and scientiﬁc contribution to the life cy-
cle of medicinal products,
(2) harmonization of technical requirements for mar-
keting authorization at EU and international level,
(3) support to the European Commission on policy
matters relevant to medicinal products.
Moreover, the agency is responsible for the eﬃcient
running of the operations at EU level including develop-
ment and maintenance of the necessary IT tools (such as
databases) and networks to support the communication
and coordination among the stakeholders.
New legislation adopted since 1995 has added a num-
ber of responsibilities, in the context of orphan desig-
nation, with the creation of the Committee for Orphan
Medicinal Products (COMP) [5]. Other tasks relate to the
conduct of clinical trials, as well as pharmacovigilance ac-
tivities for medicines for veterinary and for human use,
including thedesignandtheoperatingofvarioussystems,
such as a clinical trial database and the EudraVigilance
database for the transmission of adverse drug reactions
[7, 8].
ThescientiﬁccompetencesoftheEMEAonmedicines
for human use, are based within its scientiﬁc commit-
tees, the Committee for Proprietary Medicinal Prod-
ucts (CPMP), which is responsible for evaluating quality,
safety, and eﬃcacy and the COMP, which is responsible4 Marisa Papaluca Amati et al 2003:1 (2003)
for the evaluation of requirements for the designation of
the orphan medicinal product status.
THE EMEA IN THE LIFE CYCLE OF GENE THERAPY
MEDICINAL PRODUCTS
Regulatoryframework
Whilst the EMEA has no remit for the authorization
of the conduct of clinical trials in the EU, it is agreed that
a scientiﬁcally sound development is necessary in order
to demonstrate the eﬃcacy of the product and to exclude
any major safety problem incompatible with the safe use
of the product.
GT products must be authorized through the central-
ized procedure [1]. The application for marketing autho-
rization (MA) must be made to the EMEA as described
in the Notice to Applicants [9]. At the conclusion of the
scientiﬁc evaluation undertaken in 210 days, the opinion
of the scientiﬁc committee is transmitted to the European
Commission to be transformed into a single marketing
authorization applying to the whole European Union.
At present, the presentation of the MA application
dossier for GT products must fulﬁl the same administra-
tive and scientiﬁc requirements as for any other medici-
nal product as laid down in the legislation [6]. These in-
clude requirements relating to establishments, in which
GT medicinal products are manufactured [10], and con-
siderations on the environmental impact of the use of
gene transfer products on the deliberate release of genet-
ically modiﬁed microorganisms. At the level of market-
ing authorization applications, the CPMP will ensure that
all appropriate measures are taken to avoid adverse ef-
fects on human health of the environment, which might
arise from the deliberate release of placing on the market
genetically modiﬁed organisms (eg, genetically modiﬁed
viruses acting as gene transfer vectors).
The environmental impact of the use of gene transfer
products as far as their contained use is concerned, has
implications for the authorization and conduct of clinical
trialsastheymaypresentbiosafetyissuesrelatedtointrin-
sic safety properties and also the safe handling in relation
to environments and the wider human population. These
aspects are taken into consideration by the competent au-
thorities in member states when authorizing the conduct
of clinical trials.
Guidelinesandscientiﬁcadvice
Technical requirements useful for scientiﬁcally sound
development of GT products are established at EU level
as reference tool not only for sponsors but also for the
bodies in charge of the authorization for conducting clin-
ical trials within the member states, and for the ﬁnal pre-
marketing regulatory evaluations.
One of the tasks of the EMEA is to advise companies
on the conduct of the various tests and trials necessary to
demonstrate the quality, safety, and eﬃcacy of medicinal
products.
The advice is generally given in the form of guidelines
or scientiﬁc advice on individual products. The guidelines
are produced with the support of speciﬁc CPMP work-
ing groups, such as the Biotechnology Working Party, the
Safety Working Party, the Eﬃcacy Working Party, and the
ad hoc group on GT. Relevant guidance documents are
also produced within the framework of the International
Conference for Harmonization (ICH)—see “Future De-
velopments” section.
Sincegenetransferproductscontaingeneticandother
materials of biological origin, many of the quality con-
siderations for recombinant DNA (rDNA) products and
other biologicals manufactured by modern biotechnolog-
ical methods will apply to the manufacture of gene trans-
fer products.
Biotechnology guidelines are made available on the
EMEA web page, http://www.emea.eu.int.
In order to address the speciﬁcities of GT, the CPMP
has developed a multidisciplinary note for guidance,
whichwasadoptedinApril2001[11].Theobjectiveofthe
CPMP note for guidance is to provide recommendations
and assistance in generating data on quality, nonclinical,
and clinical aspects of gene transfer medicinal products,
intendedtosupportmarketingauthorizationapplications
within the European Union. The current version main-
tains the focus on general aspects whereas guidance on
speciﬁc therapeutic applications is addressed in other rel-
evant documents. Experts regularly involved at national
level in the evaluations concerning the clinical trials au-
thorization, provide the scientiﬁc contribution on the is-
suance of such guidelines. Further input from interested
parties is then provided during the consultation period,
whichistheusualprocedureundertakenbytheEMEAbe-
fore ﬁnalising the regulatory recommendations.
As for any new technology, a ﬂexible approach for the
control of these products is being adopted so that rec-
ommendations can be modiﬁed in the light of experience
gained from production and use, and from further devel-
opments.
Whilst the recommendations set out in the GT guide-
line should be considered to be generally applicable, indi-
vidual products may present speciﬁc quality control and
safety concerns, for example, as in the case of DNA vac-
cines intended for prophylactic use in a large number of
healthy individuals.
The production and control of each product will be
considered on a case-by-case or product-speciﬁc basis re-
ﬂecting the intended clinical use of the product.
As regulatory experience with this treatment modality
is still growing, in order to address product speciﬁc issues
and more generally scientiﬁc issues not covered by or de-
viating from existing guidance, the CPMP is able to pro-
vide Scientiﬁc Advice to Applicants on quality, nonclin-
ical and clinical aspects of their development program.
The CPMP scientiﬁc advice is made available to the spon-
sorsonrequest.Thescientiﬁcadviceisnotbindingforthe
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may need to be justiﬁed and discussed at the time of the
evaluationofthedossierformarketingauthorization.De-
tails of the procedures are provided on the EMEA web
page.
T h er e q u e s tf o rs c i e n t i ﬁ ca d v i c em a yb ep u tf o r w a r d
to the EMEA at any stage in the development of a medic-
inal product. Presubmission and brieﬁng meetings with
the sponsors are also organised at the EMEA to stream-
line the preparation of the dossier for the available regu-
latory procedures. So far, out of more than three hundred
scientiﬁcadvicesprovidedondevelopment,foursponsors
developing GT products have used this procedure.
This reﬂects the early stage of development of this in-
novative approach more often carried out in academic in-
stitutions as research initiatives than by the pharmaceuti-
cal industry.
The national authorities experts responsible for the
approval and supervision of GT provide their input to the
EMEAscientiﬁcadviceprocess.Theauthorizationofclin-
ical trials in Europe takes place at national level. In the
USA, all clinical trials are submitted for central authoriza-
tion to the FDA through the IND mechanism.
Only very few candidate products have a development
plan oriented towards regulatory procedures ultimately
leadingtotheEU-wideissuanceofamarketingauthoriza-
tion. Sixteen percent of GT clinical trials are conducted
in EU and 80% in USA; more than 87% of worldwide
GT clinical trials are in an early development (phase I–II)
[12].
The GT scientiﬁc advices issued so far have addressed
speciﬁc aspects of phase III clinical trial design, and
also the design and adequacy of nonclinical development
strategy. The medicinal products concerned were in all
cases viral vectors (adenoviral or retroviral vectors) for
therapeutic applications in oncology, cardiovascular dis-
eases, rare Mendelian conditions, and infectious diseases.
It is expected that in the future, more requests for sci-
entiﬁc advice will be lodged by sponsors, taking into ac-
count the potential opened up by the reading and anno-
tation of the human genome, the reﬁnement of vector de-
signs and types and the progress of GT research from the
early clinical phase into Phase II–III trials.
Orphanmedicinalproductdesignation
andprocedures
The EU legislation on orphan medicinal products
provides additional support for the development of those
GTproductintendedforthetreatmentofrareandserious
diseases [5]. The EMEA within the COMP has established
a procedure for providing the scientiﬁc basis for the or-
phan medicinal products designation [13].
Orphan designation can be obtained for medicinal
products intended for human use in speciﬁc medical con-
ditions following submission of a valid application to the
EMEA. Opinions on orphan medicinal products desig-
nations are based on the following cumulative criteria:
(i) the seriousness of the condition, (ii) the existence or
not of alternative methods of diagnosis, prevention, or
treatment,and(iii)eithertherarityofthecondition(con-
sidered to aﬀect not more than ﬁve in ten thousand per-
sons in the community) or the insuﬃcient return of de-
velopment investments.
The EU supports research, development, and market-
ing of orphan medicinal products, by providing incen-
tives such as protocol assistance and scientiﬁc advice from
the EMEA, direct access to the Centralized Procedure, fee
reduction for centralized applications, priority access to
EU research programs, and ten years of market exclusivity
from the date of marketing authorization.
So far, three GT medicinal products have been desig-
nated as orphan medicinal products and for one of them
a protocol assistance process has been initiated in 2002,
encompassing scientiﬁc advice on development as well as
regulatory advice.
Summaries of the designated orphan medicinal prod-
ucts are now made available to the public on the EMEA
website as of 2002. The outcomes of the EMEA activities
intheﬁeldoforphanmedicinalproductsareregularlyup-
dated and made available on the EMEA web page within
the COMP press releases.
Marketingauthorization
Up to date no marketing authorization has been is-
sued for GT medicinal products.
Under the centralized procedure, applications are
made directly to the EMEA, in charge of coordinating the
core operations. Independent assessment of the data on
quality, safety, and eﬃcacy is carried out by designated
evaluation teams located within the national competent
authorities. A subsequent scientiﬁc peer review process
is carried out by the EMEA scientiﬁc committees. The
outcome of the procedure is a CPMP scientiﬁc opinion,
which is either favourable or unfavourable. This is com-
municated to the European Commission, which in turn
is responsible for converting CPMP opinions into legally
binding decisions (eg, the granting of a marketing au-
thorization in case of a favourable opinion). For every
favourable CPMP scientiﬁc recommendation to the Eu-
ropean Commission on the granting of a marketing au-
thorization,acomprehensiveEuropeanpublicassessment
report (EPAR) reﬂecting the scientiﬁc review and conclu-
sion of the CPMP is published on the EMEA web page
for information to the public. The EPAR excludes com-
mercially conﬁdential information. The outcomes of the
EMEA centralized operations since January 1995 till June
2002 are summarized and updated regularly in the CPMP
monthlyreportsandintheannualreportsavailableonthe
EMEA website.
FUTURE DEVELOPMENTS
TheInternationalConferenceonHarmonization
oftechnicalrequirementsforregistration
ofpharmaceuticalsandtheCPMPGTexpertgroup
The International Conference on Harmonization
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initiative involving six parties, in scientiﬁc discussions of
the technical requirements to be satisﬁed to ensure qual-
ity, safety, and eﬃcacy of medicinal products.
The six members of ICH are the regulatory bodies
of the USA (Food and Drug Administration—FDA), EU
(European Commission—EMEA), Japan (MHLW), the
relevant federations of research based pharmaceutical in-
dustry, namely, the Pharmaceutical Research and Manu-
facturers of America (PhRMA), The European Federation
of Pharmaceutical Industry (EFPIA), and the Japanese
Pharmaceuticals Manufacturers Association (JPMA). The
observers are representatives of the World Health Organi-
sation (WHO), European Free Trade Association (EFTA),
and Canada.
T h eo b j e c t i v eo ft h eI C He x e r c i s ei st op r o m o t ei n -
ternational harmonization of the requirements for reg-
istration of pharmaceuticals among the three regions
EU, USA, and Japan so that medicines are developed
and made available in a timely and eﬃcient manner
to promote public health, preventing unnecessary du-
plication of clinical trials in humans, and minimizing
the use of animal testing without compromising safety
and eﬀectiveness. More information on the ICH activi-
ties can be found at the ICH website, http://www.ich.org/
ich1bis.html.
In May 2001, in the context of the ICH, the status
of the regulatory guidance documents for GT medicinal
products already issued and available in the three regions
(EU, USA, and Japan) was discussed.
While there are diﬀerences in the format of the docu-
ments, the underlying scientiﬁc principles are not funda-
mentally diﬀerent. For this rapidly evolving area, there is
a need to continue fostering the exchange of information
amongst the regions particularly in relation to emerging
scientiﬁc ﬁndings, promoting harmonized scientiﬁc un-
derstanding.
Areas of scientiﬁc importance that warrant the atten-
tion of ICH as a matter of priority, are the need to review
the dose deﬁnition and standardization of viral vectors, to
facilitate the comparison of dose-related ﬁndings in non-
clinical studies and to facilitate a better understanding of
clinical data.
Of importance is the collaborative work, involving
industry, academia, and FDA, that is being conducted
at laboratory level to establish wild-type virus reference
standard materials for adenovirus Type 5 and adeno-
associated virus. A reference standard for a retrovirus
is currently available. Plans to develop other standards
will be considered. The results of the scientiﬁc review
on GT standardization approaches and on new emerg-
ing GT technology, to be conducted at regional level may
be shared in the framework of ICH in the form of scien-
tiﬁc workshops. The ﬁrst one took in September 2002 in
Washington DC.
In order to optimize the review of GT develop-
ments, the CPMP established and ad hoc expert group
on GT. The expert group avails itself of multidisciplinary
competence from the CPMP working groups (Biotech-
nology Working Party, Eﬃcacy Working Party, Safety
Working Party, Scientiﬁc Advice review group) and exter-
nal expert on a case-by-case basis depending on the topics
on agenda.
The group provides the CPMP with updates on cur-
rentdevelopmentintheareaofGTresearch,andgivesad-
vice on the trends of such developments, and recommen-
dations for producing technical guidelines in the form
of supplementary explanatory notes or position papers
when required. The creation of the group was consid-
ered important for ensuring that the CPMP guidelines are
up-to-date and reﬂect the state-of-the-art of the technol-
ogy and to prepare EU scientiﬁc positions in such a rapid
evolving ﬁeld.
Within the ICH activities, the group will provide sub-
stantial contribution to scientiﬁc workshops and public
debates.
The scientiﬁc reports of the group are made available
on the EMEA web page thus keeping the interested public
up to date with the EU scientiﬁc and regulatory position
(eg, http://www.emea.eu.int/pdfs/human/genetherapy/
584302en.pdf).
EUdirectiveonclinicaltrials
The recently approved “GCP directive” addresses a
number of fundamental issues relating to the implemen-
tation of GCP in clinical trials. The directive is applicable
toallclinicaltrials(phaseI–IV)conductedintheEU[14].
Sponsorsarerequiredtoobtainanauthorizationfrom
the competent authority of the member state(s) in which
the clinical trial is going to be conducted. For most drugs,
this can be granted implicitly, if the authority concerned
has not informed the sponsor of any grounds for nonac-
ceptance, within a maximum of 60 days. However, writ-
ten authorization is necessary for trials involving medic-
inal products intended for GT, somatic cell therapy in-
cludingxenogeniccelltherapy,andallmedicinalproducts
containing genetically modiﬁed organisms (GMOs). Sim-
ilarly, whilst ethics committees are required to give a rea-
soned opinion within a maximum of 60 days for the pur-
pose of commencing a trial, for GT, somatic cell therapy,
or medicines containing GMO’s, an extension of 30 days
will be permitted with a further 90 days in the event of
consultation of an expert group. In the case of xenogenic
cell therapy, there will be no time limit to the authoriza-
tion period. No GT trials may be carried out which result
inmodiﬁcationstothesubject’sgermlinegeneticidentity.
The legislation also establishes the basis for exchange
of full information on the conduct of any clinical trial be-
tween the national health authorities, the EMEA, and the
European Commission through the creation of a compre-
hensive European clinical trials database.
The GCP directive is about to bring important
changestoharmonize thekey legalrequirementsandpro-
cedures for conducting clinical trials on medicinal prod-
ucts for human use in the EU. Member states are required2003:1 (2003) Regulatory Aspects of GT in the EU 7
to implement the directive into national legislation by
May 2003 and the directive is to become eﬀective as of
1 May 2004.
CONCLUSIONS
During the ﬁrst seven years of EMEA operation
(1995–2002), a number of initiatives have been set up
in order to facilitate the dialogue on the development of
medicines, and to streamline relevant regulatory proce-
dures.
Onlyaverylimited number ofGT medicinal products
have been submitted through the EU network and this re-
ﬂectsfromonesidetheongoingeﬀortsinresearch,andon
the other side the status of early development in the clini-
cal applications of GT. Scientiﬁc advice has been provided
for GT products intended for the treatment of oncology
conditions, immunological disorders, and infectious dis-
eases. The newly established procedure on orphan desig-
nation has provided incentives and advice to drug devel-
opment for rare diseases.
The CPMP has mobilized important scientiﬁc re-
sources in order to meet the regulatory challenges of this
rapidlyevolvingﬁeld.State-of-the-artscientiﬁcadvicehas
been provided on a case-by-case basis. Moreover, in order
to keep abreast with the current advances and needs in
the GT ﬁeld, the CPMP has established an ad hoc expert
group to provide additional recommendations not only
at EU but also at international level. CPMP GT guidelines
will be updated or supplemented with explanatory notes
to reﬂect the progress in experience.
Onthebasisoftheexchangeofinformationandexpe-
rience at ICH level, the group might provide suggestions
for future recommendations, position papers, or state-
ments of principle for certain speciﬁc topics.
The coming in to force of a new EU legislation to reg-
ulate clinical trials authorization and the establishment of
the European database for clinical trials are foreseen to
provide further opportunities for cooperation in the de-
velopment of GT medicinal products.
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